Keynote 024 5 Year Update Date. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in jco or elsewhere, for which the primary end point has. Os and pfs were improved with pembrolizumab plus chemotherapy versus placebo plus chemotherapy (hazard ratio [95% ci], 0.71 [0.59 to 0.85] and 0.62 [0.52 to.

Clinical trial updates provide an opportunity to disseminate additional results from studies, published in jco or elsewhere, for which the primary end point has. Os and pfs were improved with pembrolizumab plus chemotherapy versus placebo plus chemotherapy (hazard ratio [95% ci], 0.71 [0.59 to 0.85] and 0.62 [0.52 to.